Related Experiment Video
Updated: Feb 11, 2026

Identification of Growth Inhibition Phenotypes Induced by Expression of Bacterial Type III Effectors in Yeast
Published on: March 30, 2010
Mapping Effector-Phenotype Landscapes in KRAS-Driven Cancers
1Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA; Program in Genetics and Genomics, Duke University, Durham, NC, USA; Current address: Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Abstract:
Oncogenic KRAS can activate numerous effector pathways to drive malignant progression. However, the relationships between specific effectors and oncogenic phenotypes, and the extent to which these relationships vary across heterogeneous tumors, are incompletely understood. Recently in Cell Reports, a team of scientists described an innovative, combinatorial siRNA-based approach to functionally link KRAS effectors and phenotypes in a large panel of cancer cell lines. Central to this work was the identification of two major subtypes of KRAS-mutant cancers with distinct effector landscapes and tractable therapeutic vulnerabilities.
Insights
Scientists identified two KRAS-mutant cancer subtypes by linking KRAS effectors to phenotypes. This approach reveals distinct effector landscapes and potential therapeutic vulnerabilities in diverse cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Oncogenic KRAS mutations are key drivers of cancer progression.
- KRAS activates multiple effector pathways, but their specific roles in oncogenesis and tumor heterogeneity are unclear.
Purpose of the Study:
- To functionally link KRAS effector pathways to specific oncogenic phenotypes.
- To investigate the heterogeneity of KRAS-mutant cancers and identify distinct subtypes.
Main Methods:
- Utilized a combinatorial small interfering RNA (siRNA) screening approach.
- Applied the method across a large panel of cancer cell lines to assess KRAS effector functions.
Main Results:
- Identified two major subtypes of KRAS-mutant cancers.
- Characterized distinct effector pathway landscapes for each subtype.
- Uncovered specific therapeutic vulnerabilities associated with each subtype.
Conclusions:
- The study provides a novel framework for dissecting KRAS signaling networks.
- Reveals subtype-specific dependencies that could inform targeted cancer therapies.
- Highlights the importance of understanding tumor heterogeneity for effective treatment strategies.
Related Concept Videos
ATP Driven Pumps I: An Overview
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
Xylem and Transpiration-driven Transport of Resources
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
Microtubule Associated Proteins (MAPs)
Plotting of Topographic Maps
Coordinates and Map Projections

